SNY's reasonable valuation, improving top-line performance, contributions from new product launches and positive pipeline ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Sanofi has reported results from its Phase III IRAKLIA trial of Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM).

Sanofi has paid the upfront fee and committed to discovery, development and commercial milestones of over $400 million to get ...

“Both companies are ‘houses of brands’, in other words a collection of well-diversified luxury businesses serving multiple ...

Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab ...

Looking into the current session, Sanofi Inc. SNY shares are trading at $49.35, after a 0.24% increase. Moreover, over the ...

ServiceNow, AMD, Sanofi, Team and United-Guardian are part of the Zacks top Analyst Blog. Today's Research Daily features new research reports on 16 major stocks, including ServiceNow, Inc. (NOW ...

Sanofi (NASDAQ:SNY) said that a Phase 3 study of its new subcutaneous formulation of Sarclisa in the treatment of multiple ...

Sanofi has enlisted drug discovery company Alloy Therapeutics to develop an antisense oligonucleotide drug for a single, ...